Antidementia medication acetylcholinesterase inhibitors have therapeutic benefits on osteoporotic bone by attenuating osteoclastogenesis and bone resorption
Open Access
- 19 June 2023
- journal article
- research article
- Published by Wiley in Journal of Cellular Physiology
- Vol. 238 (8) , 1823-1835
Abstract
This study was designed to determine whether the use of acetylcholinesterase inhibitors (AChEIs), a group of drugs that stimulate acetylcholine receptors and are used to treat Alzheimer's disease (AD), is associated with osteoporosis protection and inhibition of osteoclast differentiation and function. Firstly, we examined the effects of AChEIs on RANKL‐induced osteoclast differentiation and function with osteoclastogenesis and bone resorption assays. Next, we investigated the impacts of AChEIs on RANKL‐induced nuclear factor κB and NFATc1 activation and expression of osteoclast marker proteins CA‐2, CTSK and NFATc1, and dissected the MAPK signaling in osteoclasts in vitro by using luciferase assay and Western blot. Finally, we assessed the in vivo efficacy of AChEIs using an ovariectomy‐induced osteoporosis mouse model, which was analyzed using microcomputed tomography, in vivo osteoclast and osteoblast parameters were assessed using histomorphometry. We found that Donepezil and Rivastigmine inhibited RANKL‐induced osteoclastogenesis and impaired osteoclastic bone resorption. Moreover, AChEIs reduced the RANKL‐induced transcription of Nfatc1, and expression of osteoclast marker genes to varying degrees (mainly Donepezil and Rivastigmine but not Galantamine). Furthermore, AChEIs variably inhibited RANKL‐induced MAPK signaling accompanied by downregulation of AChE transcription. Finally, AChEIs protected against OVX‐induced bone loss mainly by inhibiting osteoclast activity. Taken together, AChEIs (mainly Donepezil and Rivastigmine) exerted a positive effect on bone protection by inhibiting osteoclast function through MAPK and NFATc1 signaling pathways through downregulating AChE. Our findings have important clinical implications that elderly patients with dementia who are at risk of developing osteoporosis may potentially benefit from therapy with the AChEI drugs. Our study may influence drug choice in those patients with both AD and osteoporosis.Keywords
This publication has 33 references indexed in Scilit:
- Memantine and Cholinesterase Inhibitors: Complementary Mechanisms in the Treatment of Alzheimer’s DiseaseNeurotoxicity Research, 2013
- Nicotine Affects Bone Resorption and Suppresses the Expression of Cathepsin K, MMP-9 and Vacuolar-Type H+-ATPase d2 and Actin Organization in OsteoclastsPLOS ONE, 2013
- Acetylcholinesterase inhibitors and the risk of hip fracture in Alzheimer's disease patients: A case-control studyJournal of Bone and Mineral Research, 2012
- Cellular and Molecular Mechanisms of Bone RemodelingJournal of Biological Chemistry, 2010
- Signaling through the M3 Muscarinic Receptor Favors Bone Mass Accrual by Decreasing Sympathetic ActivityCell Metabolism, 2010
- High Incidence of Osteoporosis and Fractures in an Aging Post-Polio PopulationEuropean Neurology, 2009
- NF-κB modulators in osteolytic bone diseasesCytokine & Growth Factor Reviews, 2009
- Bone Loss after Temporarily Induced Muscle Paralysis by Botox Is Not Fully Recovered After 12 WeeksAnnals of the New York Academy of Sciences, 2007
- Botox induced muscle paralysis rapidly degrades boneBone, 2006
- Cloning, Sequencing, and Functional Characterization of the Rat Homologue of Receptor Activator of NF-κB LigandJournal of Bone and Mineral Research, 2000